Since 1999, anti-TNF-α therapy has been used with success in the treatment of patients suffering from rheumatoid arthritis (RA), inflammatory enterocolitis (Crohn's disease and ulcerative colitis), spondyloarthropathies, or psoriasis [2–6]. Here, TNF is linked to rheumatoid arthritis.